-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Tango Therapeutics (NASDAQ:TNGX) Trading Up 3.7%
Tango Therapeutics (NASDAQ:TNGX) Trading Up 3.7%
Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Rating) shares were up 3.7% during trading on Friday . The stock traded as high as $7.79 and last traded at $7.79. Approximately 651 shares changed hands during trading, a decline of 100% from the average daily volume of 237,348 shares. The stock had previously closed at $7.51.
Analyst Ratings Changes
Several research analysts have recently commented on TNGX shares. Wedbush raised their price target on Tango Therapeutics to $21.00 in a research report on Wednesday, November 16th. HC Wainwright upgraded Tango Therapeutics from a "neutral" rating to a "buy" rating in a research note on Thursday, October 20th.
Get Tango Therapeutics alerts:Tango Therapeutics Price Performance
The company has a market capitalization of $690.45 million, a price-to-earnings ratio of -6.81 and a beta of 1.85. The stock has a 50 day simple moving average of $7.58 and a two-hundred day simple moving average of $5.46.
Insider Buying and Selling at Tango Therapeutics
In other Tango Therapeutics news, major shareholder Boxer Capital, Llc purchased 70,394 shares of the business's stock in a transaction on Thursday, October 6th. The shares were bought at an average cost of $4.06 per share, for a total transaction of $285,799.64. Following the completion of the purchase, the insider now directly owns 7,053,642 shares in the company, valued at $28,637,786.52. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired a total of 283,000 shares of company stock worth $1,202,524 over the last ninety days. Corporate insiders own 3.70% of the company's stock.Institutional Trading of Tango Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in TNGX. Alaethes Wealth LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth about $91,000. SG Americas Securities LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth about $78,000. Ensign Peak Advisors Inc grew its holdings in shares of Tango Therapeutics by 183.4% during the second quarter. Ensign Peak Advisors Inc now owns 299,391 shares of the company's stock worth $1,356,000 after buying an additional 193,735 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Tango Therapeutics during the first quarter worth about $113,000. Finally, FMR LLC grew its holdings in shares of Tango Therapeutics by 11.0% during the second quarter. FMR LLC now owns 7,631,917 shares of the company's stock worth $34,572,000 after buying an additional 755,942 shares during the last quarter. Institutional investors and hedge funds own 77.30% of the company's stock.
Tango Therapeutics Company Profile
(Get Rating)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Featured Articles
- Get a free copy of the StockNews.com research report on Tango Therapeutics (TNGX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Rating) shares were up 3.7% during trading on Friday . The stock traded as high as $7.79 and last traded at $7.79. Approximately 651 shares changed hands during trading, a decline of 100% from the average daily volume of 237,348 shares. The stock had previously closed at $7.51.
探戈治療公司(納斯達克代碼：TNGX-GET評級)的股票在週五的交易中上漲了3.7%。該股一度漲至7.79美元，最新報7.79美元。約有651股股票在交易中易手，較日均成交量237,348股下降了100%。該股此前收盤價為7.51美元。
Analyst Ratings Changes
分析師評級發生變化
Several research analysts have recently commented on TNGX shares. Wedbush raised their price target on Tango Therapeutics to $21.00 in a research report on Wednesday, November 16th. HC Wainwright upgraded Tango Therapeutics from a "neutral" rating to a "buy" rating in a research note on Thursday, October 20th.
幾位研究分析師最近對TNGX的股票發表了評論。韋德布什在11月16日星期三的一份研究報告中將他們對Tango治療公司的目標價上調至21.00美元。在10月20日星期四的一份研究報告中，HC Wainwright將Tango治療公司的評級從中性上調至買入。
Tango Therapeutics Price Performance
探戈治療藥物性價比
The company has a market capitalization of $690.45 million, a price-to-earnings ratio of -6.81 and a beta of 1.85. The stock has a 50 day simple moving average of $7.58 and a two-hundred day simple moving average of $5.46.
該公司市值為6.9045億美元，本益比為-6.81倍，貝塔係數為1.85。該股的50日簡單移動均線切入位為7.58美元，200日簡單移動均線切入位為5.46美元。
Insider Buying and Selling at Tango Therapeutics
Tango治療公司的內幕買賣
Institutional Trading of Tango Therapeutics
探戈治療的制度性交易
A number of hedge funds and other institutional investors have recently made changes to their positions in TNGX. Alaethes Wealth LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth about $91,000. SG Americas Securities LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth about $78,000. Ensign Peak Advisors Inc grew its holdings in shares of Tango Therapeutics by 183.4% during the second quarter. Ensign Peak Advisors Inc now owns 299,391 shares of the company's stock worth $1,356,000 after buying an additional 193,735 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Tango Therapeutics during the first quarter worth about $113,000. Finally, FMR LLC grew its holdings in shares of Tango Therapeutics by 11.0% during the second quarter. FMR LLC now owns 7,631,917 shares of the company's stock worth $34,572,000 after buying an additional 755,942 shares during the last quarter. Institutional investors and hedge funds own 77.30% of the company's stock.
一些對沖基金和其他機構投資者最近改變了他們在TNGX的頭寸。Alaethes Wealth LLC在第二季度購買了Tango治療公司新的股票頭寸，價值約91,000美元。SG America Securities LLC在第二季度購買了Tango治療公司新的股票頭寸，價值約7.8萬美元。Ensign Peak Advisors Inc.在第二季度增持了探戈治療公司的股票183.4%。Ensign Peak Advisors Inc.現在擁有299,391股該公司股票，價值1,356,000美元，此前該公司在上個季度又購買了193,735股。GSA Capital Partners LLP在第一季度購買了Tango治療公司新的股票頭寸，價值約11.3萬美元。最後，FMR LLC在第二季度增持了Tango治療公司的股票11.0%。FMR LLC現在擁有該公司7,631,917股股票，價值34,572,000美元，上個季度又購買了755,942股。機構投資者和對沖基金持有該公司77.30%的股票。
Tango Therapeutics Company Profile
探戈治療公司簡介
(Get Rating)
(獲取評級)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
探戈治療公司是一家生物技術公司，負責發現和開發治療癌症的藥物。它的主要專案是TNG908，一種合成的精氨酸甲基轉移酵素5的致命小分子抑制劑，正在開發用於治療甲基硫代腺甘酸磷酸化酵素缺失的癌症。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Tango Therapeutics (TNGX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免費獲取StockNews.com關於探戈治療(TNGX)的研究報告
- MarketBeat：回顧一週12/19-12/23
- 這些鋼鐵制造商理應在2023年觀察名單上佔有一席之地
- 通脹降溫，標普500指數何去何從
- Cintas以經營槓桿擊敗通脹
- 你買下Palantir的決定可能只是個時間問題
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《探戈治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Tango治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧